10x Genomics
261 hedge funds and large institutions have $2.05B invested in 10x Genomics in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 113 increasing their positions, 77 reducing their positions, and 62 closing their positions.
69% more call options, than puts
Call options by funds: $4.01M | Put options by funds: $2.37M
47% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 77
1.35% more ownership
Funds ownership: 98.39% → 99.74% (+1.3%)
10% less funds holding
Funds holding: 290 → 261 (-29)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
42% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 62
47% less capital invested
Capital invested by funds: $3.89B → $2.05B (-$1.84B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$79.3M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$66.2M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$66M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$46.9M |
| 5 |
GIM
Generation Investment Management
London,
United Kingdom
|
+$38.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$123M |
| 2 |
FCM
Freshford Capital Management
Rye Brook,
New York
|
-$29.4M |
| 3 |
RI
RTW Investments
New York
|
-$27.5M |
| 4 |
Sands Capital Management
Arlington,
Virginia
|
-$27.4M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$26.5M |
TXG Hedge Fund Activity: Q2 2024 in Review
261 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2024, worth a combined $2.05B — down 47% from $3.89B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of TXG and 36 opened new positions — a net loss of 26 holders — while 77 trimmed existing stakes and 113 added.
The largest buyer was ARK Investment Management, adding an estimated $79.3M. The largest seller was Baillie Gifford & Co, cutting an estimated $123M.
- 261 institutional investors held 10x Genomics (TXG) as of Q2 2024, down from 290 in Q1 2024.
- Funds reported $2.05B of 10x Genomics stock for Q2 2024, down 47% quarter-over-quarter.
- 36 funds opened new 10x Genomics positions in Q2 2024 and 62 closed out, a net change of -26 holders.
- The largest 10x Genomics buyer in Q2 2024 was ARK Investment Management, an estimated $79.3M added.
- The largest 10x Genomics seller in Q2 2024 was Baillie Gifford & Co, an estimated $123M sold.
Based on aggregated 13F filings for Q2 2024.